<DOC>
	<DOCNO>NCT00235222</DOCNO>
	<brief_summary>Lipodystrophie , peripheral neuropathy mitochondrial toxicity associate stavudine standard dose The aim study evaluate efficacy reduce dos stavudine ( 30 mg b.i.d . ) HIV patient controlled viral load body weight &gt; 60 kg , receive antiretroviral therapy contain stavudine 40 mg b.i.d .</brief_summary>
	<brief_title>Evaluation Viral Efficacy Safety Reduced Dose Stavudine ( d4T ) : THE PHOENIX STUDY</brief_title>
	<detailed_description>Stavudine nucleoside inhibitor larged use HIV treatment associate mithocondrial toxicity . As still largely used developping country , evaluation reduce dose importance . A single-arm open pilot 48 week study evaluate capacity switch d4T 40 mg 30 mg bid patient body weight &gt; 60kg maintain full viral load suppression . Clinical biological evaluation carry baseline , W24 W48 . Primary end-point viral load suppression ( &lt; 400 coies/ml ) W24 . Secondary end-points : Evolution CD4 count W24 W48 , neurological examination Baseline , W24 W48 , metabolic parameter stavudine PK W24 .</detailed_description>
	<mesh_term>Stavudine</mesh_term>
	<criteria>HIV patient Patients antiretroviral treatment contain stavudine standard dos ( 40mg BID ) least 3 month Patients viral load &lt; 400 copies/ml least 3 month Patients receive antiretroviral therapy contain stavudine 30mg BID Current Opportunistic Infection Current chemotherapy cytokine treatment ( PEG , INF , IL2 ) Pregnant feed Women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Stavudine</keyword>
	<keyword>Reduced dose stavudine</keyword>
	<keyword>Viral load</keyword>
	<keyword>Peripheral neuropathy</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>